Neonatal, infant, and childhood growth following metformin versus insulin treatment for gestational diabetes: A systematic review and meta-analysis
Open accessThe DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Metformin is increasingly offered as an acceptable and economic alternative to insulin for treatment of gestational diabetes mellitus (GDM) in many countries. However, the impact of maternal metformin treatment on the trajectory of fetal, infant, and childhood growth is unknown. METHODS AND FINDINGS: PubMed, Ovid Embase, Medline, Web of Science, ClinicalTrials.gov, and the Cochrane database were systematically searched (from database inception to 26 February 2019). Outcomes of GDM-affected pregnancies randomised to treatment with metformin versus insulin were included (randomised controlled trials and prospective randomised controlled studies) from cohorts including European, American, Asian, Australian, and African women. Studies including pregnant women with pre-existing diabetes or non-diabetic women were excluded, as were trials comparing metformin treatment with oral glucose-lowering agents other than insulin. Two reviewers independently assessed articles for eligibility and risk of bias, and conflicts were resolved by a third reviewer. Outcome measures were parameters of fetal, infant, and childhood growth, including weight, height, BMI, and body composition. In total, 28 studies (n = 3,976 participants) met eligibility criteria and were included in the meta-analysis. No studies reported fetal growth parameters; 19 studies (n = 3,723 neonates) reported measures of neonatal growth. Neonates born to metformin-treated mothers had lower birth weights (mean difference -107.7 g, 95% CI -182.3 to -32.7, I2 = 83%, p = 0.005) and lower ponderal indices (mean difference -0.13 kg/m3, 95% CI -0.26 to 0.00, I2 = 0%, p = 0.04) than neonates of insulin-treated mothers. The odds of macrosomia (odds ratio [OR] 0.59, 95% CI 0.46 to 0.77, p < 0.001) and large for gestational age (OR 0.78, 95% CI 0.62 to 0.99, p = 0.04) were lower following maternal treatment with metformin compared to insulin. There was no difference in neonatal height or incidence of small for gestational age between groups. Two studies (n = 411 infants) reported measures of infant growth (18-24 months of age). In contrast to the neonatal phase, metformin-exposed infants were significantly heavier than those in the insulin-exposed group (mean difference 440 g, 95% CI 50 to 830, I2 = 4%, p = 0.03). Three studies (n = 520 children) reported mid-childhood growth parameters (5-9 years). In mid-childhood, BMI was significantly higher (mean difference 0.78 kg/m2, 95% CI 0.23 to 1.33, I2 = 7%, p = 0.005) following metformin exposure than following insulin exposure, although the difference in absolute weights between the groups was not significantly different (p = 0.09). Limited evidence (1 study with data treated as 2 cohorts) suggested that adiposity indices (abdominal [p = 0.02] and visceral [p = 0.03] fat volumes) may be higher in children born to metformin-treated compared to insulin-treated mothers. Study limitations include heterogeneity in metformin dosing, heterogeneity in diagnostic criteria for GDM, and the scarcity of reporting of childhood outcomes. CONCLUSIONS: Following intrauterine exposure to metformin for treatment of maternal GDM, neonates are significantly smaller than neonates whose mothers were treated with insulin during pregnancy. Despite lower average birth weight, metformin-exposed children appear to experience accelerated postnatal growth, resulting in heavier infants and higher BMI by mid-childhood compared to children whose mothers were treated with insulin. Such patterns of low birth weight and postnatal catch-up growth have been reported to be associated with adverse long-term cardio-metabolic outcomes. This suggests a need for further studies examining longitudinal perinatal and childhood outcomes following intrauterine metformin exposure. This review protocol was registered with PROSPERO under registration number CRD42018117503.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures















Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A follow-up study at 5-10 years showed that the offspring had higher BMI, weight-toheight ratios, waist circumferences, and a borderline increase in fat mass (88,89).”
From 15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes—2024 (2024) · cites this paper as [88]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“A meta-analysis demonstrated that metformin exposure resulted in smaller neonates with an acceleration of postnatal growth, resulting in higher BMI in childhood (88).”
From 15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes—2024 (2024) · cites this paper as [88]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & the PRISMA Group* (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-4-200908180-00135 · Cited by 37,554
Hyperglycemia and adverse pregnancy outcomes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707943 · Cited by 5,563
Scottish Intercollegiate Guidelines Network
Twaddle, S., & Qureshi, S. (2005) · Evidence-based Healthcare and Public Health · doi:10.1016/j.ehbc.2005.09.008 · Cited by 4,084
Elective induction versus spontaneous labor after sonographic diagnosis of fetal macrosomia.
Combs, C. A., Singh, N. B., & Khoury, J. C. (1993) · PubMed · Cited by 2,500
OWEN, M. R., DORAN, E., & HALESTRAP, A. P. (2000) · Biochemical Journal · doi:10.1042/bj3480607 · Cited by 2,157
Association between postnatal catch-up growth and obesity in childhood: prospective cohort study
Ong, K. K. L. (2000) · BMJ · doi:10.1136/bmj.320.7240.967 · Cited by 1,668
Metformin versus insulin for the treatment of gestational diabetes
Rowan, J. A., Hague, W. M., Gao, W., Battin, M. R., & Moore, M. P. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707193 · Cited by 1,291
Prevalence of Gestational Diabetes and Risk of Progression to Type 2 Diabetes: a Global Perspective
Zhu, Y., & Zhang, C. (2016) · Current Diabetes Reports · doi:10.1007/s11892-015-0699-x · Cited by 1,260
Research works printed but not linked: 2
- Hamadani A, Zahid S, Butt ZB. Metformin versus insulin treatment in gestational diabetes in pregnancy and their effects on neonatal birthweight. Pak J Med Sci. 2017; 11: 914– 6.
- International Diabetes Federation. IDF diabetes atlas— 8th edition Brussels: International Diabetes Federation; 2017.
Cited by
A Clinical Update on Gestational Diabetes Mellitus
Sweeting, A., Wong, J., Murphy, H. R., & Ross, G. P. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnac003 · Cited by 928
15. Management of Diabetes in Pregnancy: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s015 · Cited by 504
Epidemiology and management of gestational diabetes
Sweeting, A., Hannah, W., Backman, H., Catalano, P., Feghali, M., Herman, W. H., Hivert, M.-F., Immanuel, J., Meek, C., Oppermann, M. L., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00825-0 · Cited by 431
14. Management of Diabetes in Pregnancy:Standards of Medical Care in Diabetes—2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s014 · Cited by 381
Ornoy, A., Becker, M., Weinstein-Fudim, L., & Ergaz, Z. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22062965 · Cited by 339
“8 kg/m2) at 5–9 years of age than those of mothers who received insulin [162].”
BackgroundMethod15. Management of Diabetes in Pregnancy:Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s015 · Cited by 284
14. Management of Diabetes in Pregnancy:Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s014 · Cited by 268
15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., Ekhlaspour, L., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s015 · Cited by 252
Feig, D. S., Donovan, L. E., Zinman, B., Sanchez, J. J., Asztalos, E., Ryan, E. A., Fantus, I. G., Hutton, E., Armson, A. B., Lipscombe, L. L., et al. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30310-7 · Cited by 234
15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Hilliard, M. E., Johnson, E. L., Khunti, K., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s015 · Cited by 232
Aye, I. L. M. H., Aiken, C., Charnock‐Jones, D. S., & Smith, G. C. S. (2020) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2020.11.005 · Cited by 174
Self-citationEarly Metformin in Gestational Diabetes: A Randomized Clinical Trial
Dunne, F., Newman, C., Alvarez-Iglesias, A., Ferguson, J., Smyth, A., Browne, M., O’Shea, P., Devane, D., Gillespie, P., Bogdanet, D., et al. (2023) · JAMA · doi:10.1001/jama.2023.19869 · Cited by 90
15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes—2026
Bajaj, M. S., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Early, K. B., Brown, F. M., ChallaSivaKanaka, S., et al. (2025) · Diabetes Care · doi:10.2337/dc26-s015 · Cited by 176
Short‐ and long‐term outcomes of gestational diabetes and its treatment on fetal development
Murray, S. R., & Reynolds, R. M. (2020) · Prenatal Diagnosis · doi:10.1002/pd.5768 · Cited by 104
“Metformin crosses the placenta and has similar concentrations in fetal and maternal circulations and thus has the potential to affect the developing feto-placental unit.44 A large randomized controlled trial of metformin vs insulin for the treatment of GDM (MiG trial) showed no increased in short term adverse outcomes…”
MethodInfluentialPlacental Function and the Development of Fetal Overgrowth and Fetal Growth Restriction
Dumolt, J. H., Powell, T. L., & Jansson, T. (2021) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/j.ogc.2021.02.001 · Cited by 120
César, M. J. P., Molina‐Vega, M., Suárez-Arana, M., González‐Mesa, E., Sola-Moyano, A. P., Roldan-López, R., Romero-Narbona, F., Olveira, G., Tinahones, F. J., & González‐Romero, S. (2021) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2021.04.229 · Cited by 112
Tsakiridis, I., Giouleka, S., Mamopoulos, A., Kourtis, A., Athanasiadis, A., Filopoulou, D., & Dagklis, T. (2021) · Obstetrical & Gynecological Survey · doi:10.1097/ogx.0000000000000899 · Cited by 94
“005), compared with children whose mothers were treated with insulin(66); this growth pattern has been associated with adverse long-term cardiometabolic outcomes.(66) Additionally, according to ADA, the use of metformin is contraindicated in the presence of hypertension, preeclampsia, and high-risk of fetal growth res…”
ResultMetformin in pregnancy and risk of adverse long-term outcomes: a register-based cohort study
Brand, K. M. G., Saarelainen, L., Sõnajalg, J., Boutmy, E., Foch, C., Vääräsmäki, M., Morin-Papunen, L. C., Schlachter, J., CLUE Study Group, Hakkarainen, K. M., et al. (2022) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002363 · Cited by 110
Owen, M. D., Baker, B., SCOTT, E. M., & Forbes, K. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115759 · Cited by 98
“Whilst metformin therapy has been shown to significantly reduce the incidence of LGA, it has been reported that it may decrease birth weight to the extreme as metformin use in pregnancy is associated with an increased rate of small for gestational age (SGA) births; that is, those with a birth weight below the 10th per…”
BackgroundShpakov, A. O. (2021) · Pharmaceuticals · doi:10.3390/ph14010042 · Cited by 91
Tarry-Adkins, J. L., Aiken, C. E., & Ozanne, S. E. (2020) · PLoS Medicine · doi:10.1371/journal.pmed.1003126 · Cited by 73
“Details for the database search strategies for metformin versus insulin comparisons can be found in [29].”
BackgroundMethodInfluentialSelf-citationProgramming of cardiometabolic health: the role of maternal and fetal hyperinsulinaemia
Hufnagel, A., Dearden, L., Fernandez‐Twinn, D. S., & Ozanne, S. E. (2022) · Journal of Endocrinology · doi:10.1530/joe-21-0332 · Cited by 86
Self-citationTarry‐Adkins, J. L., Ozanne, S. E., & Aiken, C. (2021) · Scientific Reports · doi:10.1038/s41598-021-88650-5 · Cited by 84
Self-citationFeig, D. S., Sanchez, J. J., Murphy, K. E., Asztalos, E., Zinman, B., Simmons, D., Haqq, A. M., Fantus, I. G., Lipscombe, L., Armson, A., et al. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00004-9 · Cited by 61
Metformin: Past, Present, and Future
Chaudhary, S., & Kulkarni, A. (2024) · Current Diabetes Reports · doi:10.1007/s11892-024-01539-1 · Cited by 68
Wyckoff, J., Lapolla, A., Asias-Dinh, B. D., Barbour, L. A., Brown, F. M., Catalano, P. M., Corcoy, R., Renzo, G. C. D., Drobycki, N., Kautzky‐Willer, A., et al. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf288 · Cited by 60
“Having SGA status, like LGA status, is also a risk factor for childhood obesity, especially when the offspring is exposed later in life to an obe-sogenic postnatal environment (146).”
Jiang, S., Liu, A., Ma, W., Liu, X., Luo, P., Zhan, M., Zhou, X., Chen, L., & Zhang, J. (2023) · Food & Function · doi:10.1039/d3fo01701j · Cited by 58
Hou, J., Lin, Y., Zhu, C., Chen, Y., Lin, R., Lin, H., Liu, D., Guan, D., Yu, B., Wang, J., et al. (2024) · Advanced Science · doi:10.1002/advs.202402477 · Cited by 63
Efficacy and safety of metformin during pregnancy: an update
Paschou, S. Α., Shalit, A., Gerontiti, E., Athanasiadou, K. I., Kalampokas, T., Ψαλτοπούλου, Θ., Lambrinoudaki, I. V., Anastasiou, E., Wolffenbuttel, B. H. R., & Goulis, D. G. (2023) · Endocrine · doi:10.1007/s12020-023-03550-0 · Cited by 60
“BMI was signi fi cantly higher in the metformin-exposed group of the same age (MD 0.78, 95% CI 0.23 to 1.33; p = 0.005) [57].”
BackgroundInfluentialMetformin for pregnancy and beyond: the pros and cons
Newman, C., & Dunne, F. (2021) · Diabetic Medicine · doi:10.1111/dme.14700 · Cited by 49
Fornes, R., Simin, J., Nguyen, M. H., Cruz, G., Crisosto, N., van der Schaaf, M., Engstrand, L., & Brusselaers, N. (2022) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-022-00905-6 · Cited by 44
Sheng, B., Ni, J., Lv, B., Jiang, G., Lin, X., & Li, H. (2023) · Acta Diabetologica · doi:10.1007/s00592-022-02016-5 · Cited by 50
“Macrosomic fetuses in women with diabetes develop a unique pattern of overgrowth involving central deposition of subcutaneous fat in the abdominal and interscapular areas with skeletal growth remaining largely unaffected [40, 42].”
BackgroundHufnagel, A., Fernandez‐Twinn, D. S., Blackmore, H. L., Ashmore, T. J., Heaton, R. A., Jenkins, B., Koulman, A., Hargreaves, I. P., Aiken, C., & Ozanne, S. E. (2021) · The Journal of Physiology · doi:10.1113/jp281902 · Cited by 68
“Long-term data about possible impacts of metformin use in pregnancy on offspring adiposity are starting to emerge, highlighting possible increased adiposity in mid-childhood following maternal metformin treatment (Tarry-Adkins et al. 2019).”
BackgroundInfluentialSelf-citationSchoonejans, J. M., Blackmore, H. L., Ashmore, T. J., Aiken, C., Fernandez‐Twinn, D. S., & Ozanne, S. E. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158104 · Cited by 40
“that the decreased birth weight observed in metformin‐treated human GDM pregnancies is followed by increased postnatal growth, leading to heavier infants compared to insulin‐ treated GDM [51].”
BackgroundResultInfluentialSelf-citationPaavilainen, E., Tertti, K., Nikkinen, H., Veijola, R., Vääräsmäki, M., Loo, B.-M., Tossavainen, P. H., Rönnemaa, T., & Niinikoski, H. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14589 · Cited by 37
Silverii, G. A. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15749 · Cited by 33
“76,77 These mixed results concerning gastrointestinal tolerability may have several possible explanations; for example, the proportion of patients who are intolerant to metformin-IR but not to metformin-XR may be too small to be detected in clinical trials, only in large observational studies or…”
InfluentialUnravelling Polycystic Ovary Syndrome and Its Comorbidities
Kim, K.-W. (2021) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes21043 · Cited by 44
“A recent meta-analysis concluded that metformin exposure results in smaller neonates with accelerated postnatal growth, leading to a higher BMI in childhood.(61) The underlying mechanism is that metformin is transported by organic cation transporters into the mitochondrial membranes in both the fetus and placenta (in…”
BackgroundTimsit, J., Ciangura, C., Dubois‐Laforgue, D., Saint‐Martin, C., & Bellanné‐Chantelot, C. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.802423 · Cited by 39
An unwelcome inheritance: childhood obesity after diabetes in pregnancy
Meek, C. L. (2023) · Diabetologia · doi:10.1007/s00125-023-05965-w · Cited by 38
“However, a previous meta-analysis identified associations between metformin and accelerated growth postnatally, leading to an increased risk of obesity in childhood, compared with children of women treated with insulin during pregnancy [70].”
Gestational Diabetes: An Update 60 Years After O’Sullivan and Mahan
McIntyre, H. D., Kampmann, U., Dalsgaard Clausen, T., Laurie, J., & Ma, R. C. W. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae709 · Cited by 32
Xie, X., Liu, J., Pujol, I., López, A., Martínez, M. J., García-Patterson, A., Adelantado, J. M., Ginovart, G., & Corcoy, R. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9103343 · Cited by 32
“The relationship of iGWG with long-term adiposity and insulin resistance would be akin to situations such as maternal treatment with metformin [57,58] or prevention of GDM through lifestyle intervention [59].”
BackgroundManagement of type 2 diabetes in pregnancy: a narrative review
Raets, L., Ingelbrecht, A., & Benhalima, K. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1193271 · Cited by 33
“A 10% decrease in pre-pregnancy BMI has been associated with at least a 10% lower risk of preeclampsia, medically indicated preterm birth, macrosomia, and stillbirth (39).”
BackgroundInfluentialPaavilainen, E., Nyman, A. H., Niinikoski, H., Nikkinen, H., Veijola, R., Vääräsmäki, M., Tossavainen, P. H., Rönnemaa, T., & Tertti, K. (2023) · Journal of Developmental & Behavioral Pediatrics · doi:10.1097/dbp.0000000000001233 · Cited by 33
“%] in the metformin group and 14 [17.1”
BackgroundInfluentialHerath, M. P., Beckett, J. M., Hills, A. P., Byrne, N. M., & Ahuja, K. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10040835 · Cited by 31
“As reported in two recent systematic reviews, although there are no significant differences in body composition at birth [58], children exposed to metformin in utero show accelerated postnatal growth, compared to those exposed to insulin [59].”
ResultImpact of Metformin Treatment on Human Placental Energy Production and Oxidative Stress
Tarry‐Adkins, J. L., Robinson, I. G., Reynolds, R. M., Aye, I. L. M. H., Charnock‐Jones, D. S., Jenkins, B., Koulmann, A., Ozanne, S. E., & Aiken, C. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.935403 · Cited by 36
Self-citationSchoonejans, J. M., Blackmore, H. L., Ashmore, T. J., Pantaleão, L. C., Pisani, L. P., Dearden, L., Tadross, J. A., Aiken, C., Fernandez‐Twinn, D. S., & Ozanne, S. E. (2022) · Diabetologia · doi:10.1007/s00125-022-05789-0 · Cited by 34
Self-citationSciacca, L., Bianchi, C., Burlina, S., Formoso, G., Manicardi, E., Sculli, M. A., & Resi, V. (2023) · Acta Diabetologica · doi:10.1007/s00592-023-02137-5 · Cited by 33
“04) than neonates of insulintreated mothers [56].”
Gordon, H. G., Atkinson, J., Tong, S., Mehdipour, P., Cluver, C. A., Walker, S. P., Lindquist, A., & Hastie, R. M. (2024) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2024.02.316 · Cited by 31
Dearden, L., & Ozanne, S. E. (2023) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2022.0222 · Cited by 27
Self-citationWyckoff, J., Lapolla, A., Asias-Dinh, B. D., Barbour, L. A., Brown, F. M., Catalano, P. M., Corcoy, R., Renzo, G. C. D., Drobycki, N., Kautzky‐Willer, A., et al. (2025) · European Journal of Endocrinology · doi:10.1093/ejendo/lvaf116 · Cited by 31
“Developmental programming of metabolic disease suggests that males may be more affected than females and that age 2 years is likely not long enough to see differences in offspring weight or body composition that predict future obesity risk 146 .”
Diabetes: how to manage gestational diabetes mellitus
Mukherjee, S. M., & Dawson, A. (2022) · Drugs in Context · doi:10.7573/dic.2021-9-12 · Cited by 33
Translation of mechanistic advances in preeclampsia to the clinic: Long and winding road
Thadhani, R., Cerdeira, A. S., & Karumanchi, S. A. (2024) · The FASEB Journal · doi:10.1096/fj.202301808r · Cited by 32
Venkatesh, K. K., Chiang, C., Castillo, W. C., Battarbee, A., Donneyong, M. M., Harper, L. M., Costantine, M. M., Saade, G. A., Werner, E., Boggess, K., et al. (2021) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.16960 · Cited by 29
Chen, J., Yang, Y., Yu, N., Sun, W., Yang, Y., & Zhao, M. (2022) · PLoS ONE · doi:10.1371/journal.pone.0267045 · Cited by 29
“On the other hand, previous studies have found that metformin treatment of GDM can reduce newborn birth weight in a short period of time, but the long-term weight gain of children is faster than that of the insulin treatment group, and women with GDM who take metformin were more likely to gain less than the recommende…”
BackgroundPGC-1α activity and mitochondrial dysfunction in preterm infants
Mohammadi, A., Higazy, R., & Gauda, E. B. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.997619 · Cited by 27
“These findings are concerning since low birth weight followed by rapid postnatal growth puts infants at a higher risk of developing cardiovascular disease and type 2 diabetes (Nguyen et al., 2018; Tarry-Adkins et al., 2019; Estrella et al., 2021).”
BackgroundCao, Q., Hu, Y., Fu, J., Huang, X., Wu, L., Zhang, J., & Huang, W. (2021) · Journal of obstetrics and gynaecology research · doi:10.1111/jog.15044 · Cited by 26
“In a recent meta-analysis on GDM, metformin reduced neonatal birthweight and head circumference.(39) A previous meta-analysis also suggested that”
MethodNeuroprotective strategies for neonatal hypoxic-ischemic brain damage: Current status and challenges
You, Q., Lan, X., Liu, N., Du, J., Ma, L., Yang, J., Niu, J., Peng, X.-D., Jin, G., & Yu, J. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.176003 · Cited by 26
Tratamento farmacológico do diabetes na gestação
Zajdenverg, L., Dualib, P. M., Lauand, T. C. G., Reichelt, A. J., Satler, F., Façanha, C. F. S., Golbert, A., Negrato, C. A., Araújo, C. A. R., & Bertoluci, M. (2022) · Conectando Pessoas eBooks · doi:10.29327/557753.2022-13 · Cited by 51
Placental mTOR Signaling and Sexual Dimorphism in Metabolic Health across the Lifespan of Offspring
Beetch, M., & Alejandro, E. U. (2021) · Children · doi:10.3390/children8110970 · Cited by 26
“In human studies, metformin-exposed offspring are at increased risk for fetal growth restriction and catch-up growth during mid-childhood [35].”
BackgroundMetformin Disrupts Signaling and Metabolism in Fetal Hepatocytes
Swenson, K. S., Wang, D., Jones, A. K., Nash, M. J., O’Rourke, R., Takahashi, D. L., Kievit, P., Hennebold, J. D., Aagaard, K. M., Friedman, J. E., et al. (2023) · Diabetes · doi:10.2337/db23-0089 · Cited by 23
Effects of metformin treatment on pregnancy outcomes in patients with polycystic ovary syndrome
Raperport, C., Chronopoulou, E., & Homburg, R. (2021) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2021.1889366 · Cited by 26
Stephansson, O., & Sandström, A. (2024) · Journal of Internal Medicine · doi:10.1111/joim.13823 · Cited by 21
“Compared to insulin treatment for GDM, a meta-analysis on longer-term outcomes reported that metformin alters the postnatal growth trajectory, with metformin-exposed children being heavier at 18-24 months and with a higher BMI in mid-childhood (5-9 years) [114].”
Metformin in obese pregnancy has no adverse effects on cardiovascular risk in early childhood
Liu, Y., Lacey, L., Whyte, S., Quenby, S. M., Denison, F. C., Dhaun, N., Norman, J. E., Drake, A. J., & Reynolds, R. M. (2021) · Journal of Developmental Origins of Health and Disease · doi:10.1017/s2040174421000301 · Cited by 18
Quansah, D. Y., Gross, J., Gilbert, L., Pauchet, A., Horsch, A., Benhalima, K., Cosson, E., & Puder, J. J. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab791 · Cited by 19
Metformin treatment of juvenile mice alters aging-related developmental and metabolic phenotypes
Zhu, Y. X., Fang, Y., Medina, D., Bartke, A., & Yuan, R. (2021) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2021.111597 · Cited by 20
Standards of Care in Diabetes. The position of Diabetes Poland – 2024
Araszkiewicz, A., Bandurska-Stankiewicz, E. M., Borys, S., Broncel, M., Budzynski, A. Z., Cyganek, K., Cypryk, K., CYRANKA, K. M., Czupryniak, L., Dzida, G. J., et al. (2024) · Current Topics in Diabetes · doi:10.5114/ctd/183052 · Cited by 33
Management of Women with Polycystic Ovary Syndrome During Pregnancy
Valent, A. M., & Barbour, L. A. (2021) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2020.10.005 · Cited by 17
In Utero Exposure to Metformin Reduces the Fertility of Male Offspring in Adulthood
Faure, M., Khoueiry, R., Quanico, J. P., Acloque, H., Guerquin, M.-J., Bertoldo, M. J., Chevaleyre, C., Ramé, C., Fournier, I., Salzet, M., et al. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.750145 · Cited by 18
Bolte, E., Dean, T. A., Garcia, B. T., Seferovic, M. D., Sauter, K. A. D., Hummel, G. L., Bucher, M., Li, F., Hicks, J. M., Qin, X., et al. (2024) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2024.06.002 · Cited by 21
Metformin in gestational diabetes: physiological actions and clinical applications
Mason, T., Alesi, S., Fernando, M., Vanky, E., Teede, H. J., & Mousa, A. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-01049-w · Cited by 20
Kurosawa, K., Chiba, K., Noguchi, S., Nishimura, T., & Tomi, M. (2020) · Drug Metabolism and Disposition · doi:10.1124/dmd.120.000127 · Cited by 16
“were treated with insulin, but then appeared to experience accelerated postnatal growth (Tarry-Adkins et al., 2019), which might be associated with adverse long-term cardiometabolic outcomes (Eriksson et al.”
BackgroundMetformin in gestational diabetes mellitus: A double‐blind placebo‐controlled randomized trial
Tew, M. P., Tan, P. C., Saaid, R., Hong, J. G. S., & Omar, S. Z. (2021) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.13718 · Cited by 19
Metformin Perturbs Pancreatic Differentiation From Human Embryonic Stem Cells
Nguyen, L. T. V., Lim, L. Y., Ding, S. S. L., Amirruddin, N. S., Hoon, S. S., Chan, S., & Teo, A. K. K. (2021) · Diabetes · doi:10.2337/db20-0722 · Cited by 18
Crippling of Klebsiella pneumoniae virulence by metformin, N-acetylcysteine and secnidazole
Shafik, S. M., Abbas, H. A., Yousef, N. E., & Saleh, M. M. (2023) · BMC Microbiology · doi:10.1186/s12866-023-02969-9 · Cited by 19
“[45].”
Codina, M., Corcoy, R., Goya, M., Delgado, D. A., Pérez, M. B., Nivela, M. O. B., Rasero, J. L. B., Alfonso, J. B., Blanco‐Carnero, J. E., López, M. A. B., et al. (2020) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2020.05.002 · Cited by 17
Fu, J. M., Tabbara, N., TOMLINSON, G. A., Murphy, K. E., Hamilton, J. K., & Feig, D. S. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-088653 · Cited by 16
“More research is needed with more diverse patient populations in terms of ethnicity and socioeconomic status, and longer follow-up of the offspring, particularly into adolescence and adulthood, before definitive conclusions can be drawn about the long-term safety of intrauterine metformin exposure.”
Bodier, L., Lous, M. L., Isly, H., Derrien, C., & Vaduva, P. (2025) · Diabetes & Metabolism · doi:10.1016/j.diabet.2025.101622 · Cited by 21
Research progress of metformin in gestational diabetes mellitus: a narrative review
Ouyang, H., Al-Mureish, A., & Wu, N. (2021) · Annals of Palliative Medicine · doi:10.21037/apm-21-192 · Cited by 19
“Pregnant women gain weight Zhang et al. (72). found that women with GDM treated with metformin had significantly lower BMI, body mass Table 2 (continued) Author/year/region Research type Experimental group/ Control group Number of experimental/ control group (GDM) Adverse mother outcome (metformin) (decrease/increase/…”
BackgroundResultInfluentialMetformin impairs trophoblast metabolism and differentiation in a dose-dependent manner
Nashif, S. K., Mahr, R. M., Jena, S., Jo, S., Nelson, A. B., Sadowski, D., Crawford, P. A., Puchalska, P., Alejandro, E. U., Gearhart, M. D., et al. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1167097 · Cited by 17
“follow-up has demonstrated increased weight, body mass index, and adiposity at mid-childhood following in utero metformin exposure (Tarry-Adkins et al., 2019).”
BackgroundPazzagli, L., Abdi, L., Kieler, H., & Cesta, C. E. (2020) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2020.09.037 · Cited by 16
Yarandi, R. B., Amiri, M., Tehrani, F. R., & Behboudi‐Gandevani, S. (2021) · Journal of Diabetes Investigation · doi:10.1111/jdi.13603 · Cited by 17
“14 Did the review authors provide a satisfactory explanation for, and discussion of, any heterogeneity observed in the results of the review? Yes = 19 (70) Partial yes=1 (4) No = 7 (26)”
BackgroundNovel therapeutic and diagnostic approaches for preeclampsia
Vatish, M., Powys, V. R., & Cerdeira, A. S. (2023) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000870 · Cited by 14
“A metaanalysis evaluating neonatal, infant and childhood growth showed that, compared to insulin, neonates exposed to metformin are smaller but have a higher BMI inchildhood [76].”
BackgroundPaavilainen, E., Niinikoski, H., Parkkola, R., Koskensalo, K., Nikkinen, H., Veijola, R., Vääräsmäki, M., Loo, B.-M., Tossavainen, P. H., Rönnemaa, T., et al. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110780 · Cited by 13
Dutta, D., Sharma, M., Nagendra, L., Bhattacharya, S., Mohindra, R., & Yajnik, C. S. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2024.05.017 · Cited by 15
Sajjad, M. U., Henriksen, T., Roland, M. C. P., Haugen, G. N., & Michelsen, T. M. (2023) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2023.10.043 · Cited by 12
Metformin use in pregnancy: What about long‐term effects in offspring?
Toft, J. H., & Økland, I. (2024) · Acta Obstetricia Et Gynecologica Scandinavica · doi:10.1111/aogs.14878 · Cited by 15
“In contrast, the Society of Maternal-Fetal Medicine (SMFM) 6 and the National Institute for Clinical Excellence (NICE) 7 endorse metformin for the treatment of GDM.”
BackgroundInfluentialThe role of microRNAs in pregnancies complicated by maternal diabetes
Owen, M. D., Kennedy, M., Quilang, R., SCOTT, E. M., & Forbes, K. A. (2024) · Clinical Science · doi:10.1042/cs20230681 · Cited by 15
Mayadunne, T., Saadati, S., Asmelash, D., Mason, T., Vanky, E., Teede, H. J., & Mousa, A. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16418 · Cited by 17
“22,28,29 However, other studies report no effects of metformin on foetal growth or the duration of gestation, 30 with some suggesting reduced miscarriage and prolonged gestation with metformin compared with placebo.”
Focus on Metformin: Its Role and Safety in Pregnancy and Beyond
Newman, C., Rabbitt, L., Ero, A., & Dunne, F. (2023) · Drugs · doi:10.1007/s40265-023-01899-0 · Cited by 14
“It is also worth noting that although SGA has been a concern in women with T2DM, the risk of SGA infants was not increased in metformin-treated GDM women in a number of systematic reviews [81, 82], although it was noted that there was a trend for lower birth weights and a reduced lean mass in metformin-exposed infants…”
ResultBabović, I. R., Dotlić, J., Sparić, R., Jovandarić, M. Z., Andjić, M., Marjanović-Cvjetičanin, M., Akšam, S. S., Bila, J. S., Tulić, L., Kocijancic, D., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm12010323 · Cited by 11
“[46] reported that term infants whose mothers with GDM were treated with metformin had children whose birthweights were, on average, 108 g smaller than those whose GDM mothers given insulin [46].”
BackgroundHuang, D., Liang, M., Xu, B., Chen, S., Xiao, Y., Liu, H., Yin, D., Yang, J. J., Wang, L., Pan, P., et al. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1054626 · Cited by 11
Gestational diabetes: update on screening, diagnosis and maternal management
Baddock, S., Petersons, C. J., & Nolan, C. J. (2025) · Australian Prescriber · doi:10.18773/austprescr.2025.045 · Cited by 10
Semertzidou, A., Grout-Smith, H., Kalliala, I. E. J., Garg, A., Terzidou, V., Marchesi, J. R., MacIntyre, D. A., Bennett, P. R., Tsilidis, K. K., & Kyrgiou, M. (2023) · BMC Medicine · doi:10.1186/s12916-023-02758-1 · Cited by 16
Martine‐Edith, G., Johnson, W., & Petherick, E. (2023) · Diabetic Medicine · doi:10.1111/dme.15204 · Cited by 11
From clock to clock: Therapeutic target discovery for aging and age-related diseases
Chen, J., Leung, G. H. D., Leung, H., Ustiugova, A. S., Shneyderman, A., Korzinkin, M., Gennert, D. G., Pun, F. W., Aliper, A. M., Ren, F., et al. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102871 · Cited by 13
Developmental effects of in utero metformin exposure.
Carroll, D. T., Sassin, A. M., Aagaard, K. M., & GANNON, M. A. (2021) · PubMed · Cited by 13
Fox, R., Akinboro, S., Kędzia, A. W., & Niechciał, E. (2025) · Biomedicines · doi:10.3390/biomedicines13081965 · Cited by 8
Venkatesh, K. K., Wu, J., Trinh, A., Cross, S., Rice, D., Powe, C. E., Brindle, S., Andreatta, S., Bartholomew, A. B. C., MacPherson, C., et al. (2023) · American Journal of Perinatology · doi:10.1055/s-0043-1777334 · Cited by 9
“11,12 Also, 20 to 40% of individuals who initiate metformin will subsequently require insulin during pregnancy to achieve glycemic control.”
BackgroundWu, R., & Li, Z. (2024) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-024-07483-5 · Cited by 8
“In addition, studies [12, 13] have shown that metformin may improve maternal and neonatal outcomes.”
Venkatesh, K. K., MacPherson, C., Clifton, R. G., Powe, C. E., Bartholomew, A. B. C., Gregory, D., Trinh, A., McAlearney, A. S., Fiechtner, L. G., Catalano, P. M., et al. (2024) · BMJ Open · doi:10.1136/bmjopen-2024-091176 · Cited by 9
“25 There will be 80% power to rule out an effect size of at least 0.149 SD, or a 0.27 unit difference in BMI or a 0.25 kg mean difference.”
Influential
Metadata
- Authors
- Tarry-Adkins, J. L., Aiken, C. E., & Ozanne, S. E.
- Affiliations
- University of Cambridge (GB)
- Venue
- PLoS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2019-08-06
- Volume
- 16
- Issue
- 8
- Pages
- e1002848
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- PMC
- PMC6684046
- OpenAlex
- W2963238421
- Cited by
- 251
- References
- 77
- Citations by year
- 2026: 25 · 2025: 28 · 2024: 37 · 2023: 59 · 2022: 35 · 2021: 41 · 2020: 23 · 2019: 3
- FWCI
- 4.03
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Apollo (University of Cambridge) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Apollo
- Funders
- British Heart Foundation (RG/17/12/33167)
- Medical Research Council (MC_ UU_12012/4)
- Addenbrooke's Charitable Trust, Cambridge University Hospitals (GB)
- Isaac Newton Trust
- Wellcome Trust
- Topics
- Health Sciences › Medicine › Obstetrics and Gynecology › Gestational Diabetes Research and Management
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Birth, Development, and Health
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
- Keywords
- gestational diabetes mellitus, metformin, insulin therapy, neonatal growth, infant growth, child growth, birth weight, macrosomia, large for gestational age, small for gestational age, body composition, fetal growth, childhood obesity risk, child height, child weight gain, childhood adiposity
- MeSH terms
- Child Development, Child, Preschool, Female, Humans, Hypoglycemic Agents, Infant, Infant, Newborn, Insulin, Metformin, Pregnancy, Diabetes, Gestational
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.